Table 2 Characteristics of individual treatment arms where genotyping was performed (n = 175).
Characteristic | n (%) |
|---|---|
Drug regimen | |
non-artemisinin monotherapy | 68 (39%) |
non-artemisinin combination therapy | 29 (17%) |
artemisinin monotherapy | 6 (3%) |
artemisinin combination therapy | 72 (41%) |
Total number of patients requiring genotyping * | |
1–9 | 42 (24%) |
10–19 | 30 (17%) |
20–49 | 54 (31%) |
≥50 | 30 (17%) |
no samples to genotype | 8 (5%) |
data not available | 11 (6%) |
Percent of samples successfully genotyped † | |
≤50% | 14 (9%) |
51% – 90% | 46 (29%) |
91% – 99% | 25 (16%) |
100% | 71 (46%) |
Percent of successfully genotyped samples classified as new infections | |
0% | 20 (13%) |
1% – 24% | 25 (16%) |
25% – 49% | 33 (21%) |
50% – 74% | 41 (26%) |
75% – 99% | 24 (15%) |
100% | 12 (8%) |